Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 2001 - 2100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 2001 | 26735417 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2002 | 26735448 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2003 | 26735457 |
US |
51 | 2 |
Dermatitis atopic, Pruritus, Swelling, Rash, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, DELGOCITINIB, NEMOLIZUMAB-ILTO, |
||||
| 2004 | 26735495 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2005 | 26735511 |
US |
80 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2006 | 26735525 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2007 | 26735536 |
US |
21 | 2 |
Dermatitis atopic, Pain of skin, Movement disorder, |
||||
DUPILUMAB, |
||||
| 2008 | 26735549 |
US |
58 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2009 | 26735562 |
US |
22 | 1 |
Injection site pain, Dermatitis atopic, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 2010 | 26735572 |
US |
2 | |
Irritable bowel syndrome, Dermatitis atopic, Erythema, Inappropriate schedule of product administration, |
||||
DUPILUMAB, MOMETASONE FUROATE, |
||||
| 2011 | 26735594 |
US |
47 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2012 | 26735598 |
US |
69 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2013 | 26735613 |
US |
27 | 2 |
Dermatitis atopic, Dermatitis allergic, Neurodermatitis, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 2014 | 26735619 |
US |
77 | 2 |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 2015 | 26735622 |
US |
40 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2016 | 26735630 |
US |
31 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, RUXOLITINIB, |
||||
| 2017 | 26735636 |
US |
58 | 2 |
Eye pruritus, Myalgia, Eye discharge, Diplopia, Eye irritation, Eye disorder, Dermatitis atopic, Hypersensitivity, |
||||
DUPILUMAB, |
||||
| 2018 | 26735638 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, ATORVASTATIN CALCIUM, LOSARTAN POTASSIUM, LOSARTAN, |
||||
| 2019 | 26735661 |
US |
47 | 2 |
Dermatitis atopic, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 2020 | 26735664 |
US |
64 | 2 |
Injection site erythema, Injection site rash, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2021 | 26735668 |
US |
2 | |
Gastroenteritis viral, Dermatitis atopic, Drug effect less than expected, |
||||
DUPILUMAB, ALBUTEROL SULFATE, TRETINOIN, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, DEXMETHYLPHENIDATE HYDROCHLORIDE, |
||||
| 2022 | 26735690 |
US |
32 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2023 | 26735701 |
US |
26 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2024 | 26735709 |
US |
1 | |
Dermatitis atopic, Product use complaint, |
||||
DUPILUMAB, |
||||
| 2025 | 26735759 |
US |
52 | 1 |
Ocular hyperaemia, Eyelid margin crusting, Dermatitis contact, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2026 | 26735764 |
US |
2 | |
Dermatitis atopic, Skin exfoliation, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2027 | 26735773 |
US |
45 | 2 |
Pruritus, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2028 | 26735781 |
US |
9 | 2 |
Dermatitis atopic, Pruritus, Skin exfoliation, Dry skin, |
||||
DUPILUMAB, |
||||
| 2029 | 26735792 |
US |
2 | |
Pneumonia, Influenza, Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2030 | 26735797 |
US |
13 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2031 | 26735799 |
US |
88 | 2 |
Dermatitis atopic, Rash, Pruritus, Skin exfoliation, Papule, Skin mass, |
||||
DUPILUMAB, |
||||
| 2032 | 26735801 |
US |
19 | 2 |
Dermatitis atopic, Dermatitis allergic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2033 | 26735802 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2034 | 26735815 |
US |
55 | 2 |
Fatigue, Dermatitis atopic, Rash erythematous, Pruritus, |
||||
DUPILUMAB, SOTATERCEPT-CSRK, TREPROSTINIL, |
||||
| 2035 | 26735817 |
US |
73 | 2 |
Nodule, Discomfort, Stress, Pruritus, Dermatitis atopic, Injection site pain, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 2036 | 26735840 |
US |
34 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2037 | 26735853 |
US |
72 | 1 |
Dermatitis atopic, Rash pruritic, |
||||
DUPILUMAB, |
||||
| 2038 | 26735859 |
US |
2 | |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2039 | 26735873 |
US |
24 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2040 | 26735880 |
US |
30 | 2 |
Skin exfoliation, Skin swelling, Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2041 | 26735894 |
US |
63 | 1 |
Dermatitis atopic, Rash, Skin swelling, Pruritus, Dry eye, |
||||
DUPILUMAB, |
||||
| 2042 | 26735900 |
US |
35 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2043 | 26735905 |
US |
43 | 1 |
Dermatitis atopic, Product dose omission issue, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 2044 | 26735918 |
US |
6 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2045 | 26735941 |
US |
4 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2046 | 26735955 |
US |
36 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2047 | 26735958 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2048 | 26735971 |
US |
77 | 1 |
Dermatitis atopic, Rash pruritic, |
||||
DUPILUMAB, |
||||
| 2049 | 26735972 |
US |
37 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2050 | 26735982 |
US |
1 | |
Dermatitis atopic, Product dose omission in error, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2051 | 26735992 |
US |
43 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2052 | 26735996 |
US |
1 | |
Dermatitis atopic, Injection site discharge, |
||||
DUPILUMAB, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, CETIRIZINE HYDROCHLORIDE, |
||||
| 2053 | 26736014 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2054 | 26736042 |
US |
56 | 2 |
Dermatitis atopic, Eczema, Pruritus, Therapeutic response shortened, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2055 | 26736053 |
US |
21 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2056 | 26736058 |
US |
23 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2057 | 26728965 |
US |
2 | |
Dermatitis atopic, Dermatitis allergic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2058 | 26729017 |
US |
41 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2059 | 26729044 |
US |
1 | |
Dermatitis atopic, Haemorrhage, Rash, |
||||
DUPILUMAB, DOXAZOSIN MESYLATE, ALUMINUM HYDROXIDE AND MAGNESIUM CARBONATE, MELOXICAM, OLMESARTAN MEDOXOMIL, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ROSUVASTATIN CALCIUM, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, CALCIUM CARBONATE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ERGOCALCIFEROL, |
||||
| 2060 | 26729094 |
US |
2 | |
Colitis microscopic, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2061 | 26729104 |
US |
2 | |
Skin discomfort, Sleep disorder due to a general medical condition, Dermatitis atopic, Rash, |
||||
DUPILUMAB, NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, CETIRIZINE HCL, CETIRIZINE, |
||||
| 2062 | 26729121 |
US |
83 | 1 |
Urticaria, Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, BETAMETHASONE DIPROPIONATE, CLOPIDOGREL, CLOPIDOGREL BISULFATE, FINASTERIDE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TAMSULOSIN HYDROCHLORIDE, |
||||
| 2063 | 26729166 |
US |
2 | |
Nervousness, Eczema, Product dose omission issue, Dermatitis atopic, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, LORATADINE, LORATADINE ORAL, |
||||
| 2064 | 26729722 |
US |
40 | 2 |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2065 | 26729744 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2066 | 26729819 |
US |
2 | |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2067 | 26729833 |
US |
20 | 2 |
Sleep disorder due to a general medical condition, Dermatitis atopic, Pruritus, Skin fissures, Dry skin, Skin exfoliation, Injection site pain, |
||||
DUPILUMAB, AMPHETAMINE, AMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 2068 | 26729877 |
US |
81 | 1 |
Diarrhoea, Dry skin, Skin fissures, Fall, Asthenia, Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, SIMVASTATIN, ERGOCALCIFEROL, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, LEVOTHYROXINE SODIUM, FISH OIL, CYANOCOBALAMIN, |
||||
| 2069 | 26729903 |
US |
48 | 2 |
Dermatitis atopic, Irritability, Drug ineffective, |
||||
DUPILUMAB, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, LOSARTAN POTASSIUM, LOSARTAN, TIRZEPATIDE, NEMOLIZUMAB-ILTO, LEVOCETIRIZINE DIHYDROCHLORIDE, |
||||
| 2070 | 26729914 |
US |
2 | |
Injection site pain, Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, AMLODIPINE BESYLATE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, PANCRELIPASE, EPINEPHRINE, KETOCONAZOLE, KETOCONAZOLE FOAM, KETOCONAZOLE CREAM, 2%, KETOCONAZOLE, KETOCONAZOLE FOAM, KETOCONAZOLE CREAM, 2%, LOSARTAN POTASSIUM, LOSARTAN, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, EVOLOCUMAB, NEMOLIZUMAB-ILTO, |
||||
| 2071 | 26729990 |
US |
25 | 1 |
Psoriasis, Drug ineffective, Eczema, Dry skin, Dermatitis atopic, |
||||
DUPILUMAB, MINOXIDIL, MINOXIDIL FOAM 5% (WOMENS), FINASTERIDE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 2072 | 26730014 |
US |
1 | |
Limb injury, Skin exfoliation, Dermatitis atopic, |
||||
DUPILUMAB, ALLOPURINOL, FLUTICASONE PROPIONATE, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 2073 | 26730017 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2074 | 26730059 |
US |
23 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2075 | 26730068 |
US |
49 | 1 |
Dermatitis atopic, Rash, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, LISINOPRIL, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, INSULIN ASPART, |
||||
| 2076 | 26730069 |
US |
1 | |
Arthralgia, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2077 | 26730086 |
US |
63 | 2 |
Sleep disorder due to a general medical condition, Dermatitis atopic, Rash, Discomfort, Therapeutic response decreased, |
||||
DUPILUMAB, UPADACITINIB, |
||||
| 2078 | 26730090 |
US |
1 | |
Pruritus, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, RUXOLITINIB, |
||||
| 2079 | 26730342 |
US |
1 | |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2080 | 26730346 |
US |
25 | 2 |
Dry skin, Viral infection, Oropharyngeal pain, Erythema, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2081 | 26730461 |
US |
52 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2082 | 26730469 |
US |
1 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2083 | 26730618 |
US |
56 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2084 | 26730632 |
US |
1 | |
Dermatitis atopic, Blister, |
||||
DUPILUMAB, |
||||
| 2085 | 26731299 |
US |
53 | |
Sinus disorder, Dermatitis atopic, Intentional product misuse, Intentional overdose, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 2086 | 26723098 |
US |
1 | |
Dermatitis atopic, |
||||
LEBRIKIZUMAB-LBKZ, |
||||
| 2087 | 26723780 |
US |
1 | |
Dermatitis atopic, Rash erythematous, |
||||
DUPILUMAB, |
||||
| 2088 | 26723790 |
US |
9 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2089 | 26723806 |
US |
39 | 2 |
Dermatitis atopic, Rash pruritic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2090 | 26723965 |
US |
35 | 2 |
Seasonal allergy, Skin fissures, Swelling of eyelid, Skin exfoliation, Eye discharge, Erythema, Dermatitis atopic, Acne, |
||||
DUPILUMAB, |
||||
| 2091 | 26724037 |
US |
9 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2092 | 26724046 |
US |
58 | 2 |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2093 | 26724142 |
US |
1 | |
Seasonal allergy, Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2094 | 26724214 |
US |
12 | 2 |
Nausea, Abdominal discomfort, Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 2095 | 26724217 |
US |
11 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2096 | 26724238 |
US |
2 | |
Dermatitis atopic, Dry skin, Skin discolouration, |
||||
DUPILUMAB, |
||||
| 2097 | 26724239 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2098 | 26724240 |
US |
22 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2099 | 26724249 |
US |
23 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2100 | 26724269 |
US |
41 | 1 |
Dermatitis atopic, Erythema, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30